Atlas Venture, a prominent venture capital firm specializing in biotech innovation, has successfully closed its fourteenth fund with $450 million raised in an oversubscribed fundraising effort. This fund will allow Atlas to continue its collaboration with skilled entrepreneurs to establish and invest in new biotech firms aimed at delivering new treatments to patients.
In a joint statement, the team at Atlas emphasized their disciplined approach and steadfast belief in a focused venture creation strategy. This strategy allows them to build biotechnology companies across a wide variety of disease areas and business models. They expressed gratitude to their longstanding group of limited partners (LPs) for their substantial support throughout this fundraising.
With over thirty years of experience, Atlas Venture has raised multiple funds and boasts a diverse group of long-term institutional investors. The firm has a notable track record of building and investing in innovative biotech startups, and since the closure of Fund XIII in 2022, they have seen significant successes. Several of their portfolio companies, including Nimbus’ Tyk2 program and Mariana Oncology, have been acquired by pharmaceutical partners. Others, like Disc Medicine and Q32 Bio, have gone public, while Day One Biopharmaceuticals celebrated its first FDA approval.
Over the past two years, Atlas Venture has launched 16 new biotech companies and appointed around 100 executives to its portfolio. The companies under Atlas’ umbrella currently have nearly 50 clinical trials underway, all focused on developing new therapeutic solutions for patients.
Jean-François (JF) Formela, who initiated biotech investing at Atlas back in 1993, will remain engaged with his portfolio and other firm activities but has decided to step back from making new investments following the closure of Fund XIV. JF expressed his pride in Atlas’s evolution and is eager to continue working with partners and the broader biopharma community toward the collective goal of advancing groundbreaking medicinal solutions.
Atlas Venture remains committed to its altruistic mission of translating high-impact science into life-saving medicines. Through its strategic focus on biotech startups, it is poised to make significant contributions to the healthcare landscape.
In summary, Atlas Venture’s successful fundraising for its fourteenth fund marks a significant milestone in its ongoing commitment to foster innovative biotech solutions. As it continues to grow and expand its portfolio, the firm reinforces its dedication to advancing medicine for the benefit of patients worldwide. This positive momentum suggests a bright future for both the firm and the biotech industry as a whole.